WEST PHARMACEUTICAL SERVICES INC

West Pharmaceutical Services, Inc. and Daikyo Seiko, Ltd. have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements, effective July 14, 2026. These agreements, largely similar to previous ones, facilitate technology sharing for pharmaceutical product components and establish distribution rights. West maintains a 49% ownership in Daikyo, and all agreements are set for a 10-year term.

West Pharmaceutical Services, Inc. announced the appointment of Michel Lagarde as its new President and Chief Executive Officer, effective August 31, 2026. Mr. Lagarde, previously Executive Vice President and COO at Thermo Fisher Scientific, will also join the Board of Directors. He succeeds Eric M. Green, who will retire from his roles as President, CEO, and Board Chair on the same date. Robert F. Friel, the current Lead Independent Director, will become the new Board Chair. Mr. Lagarde's compensation package includes an annual base salary of $1,175,000, a target annual incentive award of 125% of his salary, and significant equity awards.

West Pharmaceutical Services Inc. reported that it is now fully operational globally following a material cybersecurity attack detected on May 4, 2026. The incident involved data exfiltration and system encryption, prompting the company to take systems offline and engage experts. Remediation efforts have restored core enterprise systems and critical manufacturing processes. Based on the ongoing investigation, the company believes the incident will not materially impact its 2026 second-quarter and full-year financial guidance.

West Pharmaceutical Services, Inc. disclosed a material cybersecurity attack that occurred on May 7, 2026, involving data exfiltration and system encryption. The company detected the intrusion on May 4, 2026, and responded by taking systems offline globally, notifying law enforcement, and engaging cyber-forensic experts. While core enterprise systems are restored and critical operations have restarted at some sites, the incident has temporarily disrupted global business operations, and the full financial impact is yet to be determined.

West Pharmaceutical Services, Inc. held its 2026 Annual Meeting of Shareholders virtually on May 4, 2026. Shareholders elected eleven director nominees, approved the non-binding advisory vote on executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year. Additionally, a shareholder proposal for an Independent Board Chair Policy was not approved.

WEST PHARMACEUTICAL SERVICES INC reported strong first-quarter results for 2026. Net sales increased by 21.04% to $844.9 million, up from $698.0 million in the prior year. Gross profit also saw a significant rise of 27.81% to $296.4 million, compared to $231.9 million in Q1 2025. These figures indicate robust growth for the company.

West Pharmaceutical Services reported a strong first quarter for 2026, with net sales increasing 21.0% to $844.9 million and adjusted-diluted EPS rising 46.9% to $2.13. This performance was driven by robust organic growth of 15.3%, particularly in High Value Products Components and Delivery Devices, including GLP-1 and non-GLP-1 revenues. As a result of these strong results and anticipated continued momentum, the company has raised its full-year 2026 net sales and adjusted-diluted EPS guidance.